Lymphoma Clinical Trials

Showing 1561-1580 of 2,926 trials

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

NCT03383055

This is a prospective, interventional study administering 2 doses of the experimental vaccine (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative) undergoing autologous hematopoietic cell transplantation (HCT) for lymphoma or myeloma on days 28 and 56 post-HCT. The absolute number of adaptive NK cells (CD56dimCD57+NKG2C+) at various days will be compared.

LymphomaMultiple Myeloma

Masonic Cancer Center, University of Minnesota28 participantsStarted Nov 2018

Minneapolis, Minnesota, United States

COMPLETEDPhase 1/2

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

NCT00603668

This study will test different doses of anti-CD74 antibody in patients with NHL and/or CLL.

Chronic Lymphocytic Lymphoma

Gilead Sciences19 participantsStarted Aug 2008

Birmingham, Alabama, United States • Washington D.C., District of Columbia, United States • Orlando, Florida, United States +2 more locations

TERMINATEDPhase 1

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

NCT00054834

The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.

Non-Hodgkins Lymphoma

Gilead Sciences27 participantsStarted Mar 2003

Philadelphia, Pennsylvania, United States • Houston, Texas, United States

UNKNOWNPhase 2/3

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

NCT00003338

RATIONALE: Diagnostic imaging procedures, such as radiolabeled monoclonal antibodies, may improve the ability to detect the residual disease in patients who have been treated for non-Hodgkin's lymphoma. PURPOSE: Phase II/III trial to study the effectiveness of monoclonal antibodies in detecting residual disease in patients who have been treated for non-Hodgkin's lymphoma.

Lymphoma

Gilead Sciences60 participantsStarted Mar 1997

Los Angeles, California, United States • Baltimore, Maryland, United States • Cuyahoga Falls, Ohio, United States +5 more locations

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Related Searches

The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19

A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Radiation Free Chemotherapy for Early Hodgkin Lymphoma

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

TGR1202 in Relapsed and Refractory Follicular Lymphoma

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Chronic Lymphoid Malignancies Markers

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)